Prolactinoma medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Prolactinoma}} | {{Prolactinoma}} | ||
{{CMG}};{{AE}}{{Anmol}},{{Faizan}} | {{CMG}}; {{AE}}{{Anmol}}, {{Faizan}} | ||
==Overview== | ==Overview== | ||
Medical therapy for prolactinoma includes [[dopamine agonists]] (either [[cabergoline]] or [[bromocriptine]]). The goals of treatment include lowering the [[prolactin]] secretion to normal, reduction of [[tumor]] size, correction of any [[visual]] abnormalities, and restoration of normal [[pituitary]] function. | Medical therapy for prolactinoma includes [[dopamine agonists]] (either [[cabergoline]] or [[bromocriptine]]). The goals of treatment include lowering the [[prolactin]] secretion to normal, reduction of [[tumor]] size, correction of any [[visual]] abnormalities, and restoration of normal [[pituitary]] function. | ||
Revision as of 19:46, 21 September 2017
|
Prolactinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prolactinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Prolactinoma medical therapy |
|
Risk calculators and risk factors for Prolactinoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2], Faizan Sheraz, M.D. [3]
Overview
Medical therapy for prolactinoma includes dopamine agonists (either cabergoline or bromocriptine). The goals of treatment include lowering the prolactin secretion to normal, reduction of tumor size, correction of any visual abnormalities, and restoration of normal pituitary function.
Medical Therapy
- Medical therapy for prolactinoma includes dopamine agonists (cabergoline or bromocriptine).[1]
- Preferred regimen: Cabergoline 0.25 mg PO twice weekly or 0.5 mg PO once per week
- The dose may be gradually increased every 4 weeks as needed
- The maximum dose can be administered up to 1 mg PO twice per week
- Alternative regimen: Bromocriptine 1.25 mg PO once daily at bedtime for 1 week
- The dose may be gradually increased every 3 to 7 days as needed and taken in divided doses
- Preferred regimen: Cabergoline 0.25 mg PO twice weekly or 0.5 mg PO once per week
- These drugs reduce the tumor size in approximately 85% of cases and lower the prolactin concentration to normal in more than 90% of patients.
- Both drugs have been approved by the U.S Food and Drug Administration for the treatment of hyperprolactinemia.
Medical Therapy in pregnancy
- Bromocriptine is considered safe in pregnancy.[1]
Indications for withdrawal of dopamine agonist therapy
- Dopamine therapy can be tapered down to lower doses if the patient fulfills the following criteria:[1]
- Normal prolactin level for at least 2 years.
- Reduction in tumor size by at least 50%.
- No compression of optic chiasm.
- Drug cessation can be tried if:
- Cavernous sinus invasion is not present.
Radiation Therapy
Rarely, radiation therapy is used if medical therapy and surgery fail to reduce prolactin concentration. Depending on the size and location of the tumor, radiation is delivered either in low doses over the course of 5 to 6 weeks or in a single high dose. Radiation therapy is effective in approximately 30% of cases.